A Phase I Study of E7 TCR T Cell Immunotherapy for High-Grade Cervical Intraepithelial Neoplasia
Latest Information Update: 04 Nov 2021
At a glance
- Drugs KITE 439 (Primary)
- Indications Cervical intraepithelial neoplasia
- Focus Adverse reactions
Most Recent Events
- 14 Jul 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 11 Jul 2020 Planned initiation date changed to 17 Jul 2020.
- 25 Jun 2020 Planned initiation date changed from 30 Jun 2020 to 1 Jul 2020.